Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Integra Lifesciences (IART)

Integra LifeSciences Q3 revenue rises 2.3% to $411.2 million; adjusted EPS $0.59

Positive Impact 3 of 5 earnings

Integra LifeSciences reported third-quarter 2026 revenue of $411.2 million, up 2.3% from the prior year, and GAAP earnings of $0.19 per diluted share versus a loss of $(0.07) a year earlier. The company kept its full-year 2026 guidance consistent with its October 2, 2026 outlook, but expects fourth-quarter reported revenue to decline 0.5% to 5.2%, citing the Cincinnati facility disruption and softer Tissue Reconstruction results.

Key points

  • Q3 revenue $411.2 million, up 2.3% reported and 2.5% organic; GAAP EPS $0.19 vs. $(0.07), adjusted EPS $0.59 vs. $0.54
  • Full-year 2026 revenue guidance $1.634 billion to $1.654 billion; adjusted EPS guidance $2.30 to $2.40, consistent with October 2, 2026 outlook
  • Fourth-quarter 2026 adjusted EPS guidance $0.61 to $0.71; reported revenue expected to decline 0.5% to 5.2%
  • Completed $2.1 billion debt refinancing on October 19, 2026; Q3 operating cash flow $96.0 million

The filing

CompanyIntegra Lifesciences (IART)
Form8-K, current report
Filed with the SECOct 21, 2026, 6:15 AM ET
Accession number0000917520-26-000073

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.